ABL1 is an inclusion eligibility criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

AFF1 is an inclusion eligibility criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains AFF1 status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

ASXL1 is altered in 11.27% of secondary myelodysplastic syndrome patients [2].

ASXL1 is an inclusion eligibility criterion in 2 clinical trials for secondary myelodysplastic syndrome, of which 1 is open and 1 is closed. Of the trials that contain ASXL1 status and secondary myelodysplastic syndrome as inclusion criteria, 2 are phase 2 (1 open) [3].

BCR is an inclusion eligibility criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains BCR status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

DEK is an inclusion eligibility criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains DEK status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

ELL is an inclusion eligibility criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains ELL status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

KMT2A is altered in 2.0% of secondary myelodysplastic syndrome patients [2].

KMT2A is an inclusion eligibility criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

MECOM is an inclusion eligibility criterion in 4 clinical trials for secondary myelodysplastic syndrome, of which 2 are open and 2 are closed. Of the trials that contain MECOM status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [3].

MLF1 is an inclusion eligibility criterion in 3 clinical trials for secondary myelodysplastic syndrome, of which 1 is open and 2 are closed. Of the trials that contain MLF1 status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains MLLT1 status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains MLLT10 status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains MLLT3 status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains MLLT4 status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

NPM1 is an inclusion eligibility criterion in 3 clinical trials for secondary myelodysplastic syndrome, of which 1 is open and 2 are closed. Of the trials that contain NPM1 status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].

NRAS is altered in 2.82% of secondary myelodysplastic syndrome patients [2].

NRAS is an inclusion eligibility criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (0 open) [3].

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains NRIP3 status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

NUP214 is an inclusion eligibility criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains NUP214 status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 4 clinical trials for secondary myelodysplastic syndrome, of which 2 are open and 2 are closed. Of the trials that contain RPN1 status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [3].

RUNX1 is altered in 5.63% of secondary myelodysplastic syndrome patients [2].

RUNX1 is an inclusion eligibility criterion in 2 clinical trials for secondary myelodysplastic syndrome, of which 1 is open and 1 is closed. Of the trials that contain RUNX1 status and secondary myelodysplastic syndrome as inclusion criteria, 2 are phase 2 (1 open) [3].

SETBP1 is altered in 1.41% of secondary myelodysplastic syndrome patients [2].

SETBP1 is an inclusion eligibility criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 0 are open and 1 is closed. Of the trial that contains SETBP1 status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (0 open) [3].

TP53 is altered in 42.25% of secondary myelodysplastic syndrome patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].